Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rofecoxib

Known as: 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one, 4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone, rofecoxib [Chemical/Ingredient] 
A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
BACKGROUND & AIMS In human and animal studies, nonsteroidal anti-inflammatory drugs have been associated with a reduced risk of… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Inflammatory mechanisms have been implicated in Alzheimer's disease (AD) and might be mediated via the COX-2 enzyme. Previous… Expand
  • figure 1
  • table 1
  • table 2
  • table 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
  • Eric J. Topol
  • The New England journal of medicine
  • 2004
  • Corpus ID: 12516952
On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
CONTEXT Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2000
Highly Cited
2000
  • Oren, Áine, +9 authors CHNITZER
  • 2000
  • Corpus ID: 43450401
A BSTRACT Background Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking… Expand
  • figure 1
  • table 4
  • table 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
BACKGROUND Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
CONTEXT Nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal (GI) toxic effects, such as upper GI tract… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 12
Is this relevant?
Highly Cited
1999
Highly Cited
1999
The beneficial actions of nonsteroid anti-inflammatory drugs (NSAID) can be associated with inhibition of cyclo-oxygenase (COX)-2… Expand
Is this relevant?